Physician profile
Kumar S Mandal
NPI 1689676884
$2,496.68
in general payments reported to CMS, 2019-2025
20 companies · $667 in 2025
The $667 reported for 2025 was more than what 79% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $243 · 2021: $387 · 2022: $239 · 2023: $284 · 2024: $312 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $717.13 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $548.14 | 2019-2025 | |
| Abbvie INC. | $226.88 | 2021-2025 | |
| Lilly USA, LLC | $151.92 | 2019-2024 | Zepbound, Mounjaro |
| Amgen INC. | $127.76 | 2019-2024 | Krystexxa, Repatha, Otezla |
| Pfizer INC. | $127.38 | 2021-2025 | |
| Tactile Systems Technology INC | $84.66 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Abbott Laboratories | $76.38 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $72.69 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.31 | 2019-2024 | Tradjenta, Jardiance |
| Allergan, INC. | $49.01 | 2020 | |
| Exact Sciences Corporation | $46.51 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $42.95 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $32.16 | 2025 | Strensiq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $19.90 | 2023 | Accrufer |
| Daiichi Sankyo INC. | $18.10 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.15 | 2019 | |
| Astellas Pharma US INC | $14.87 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $12.72 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Mandal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.